Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer.

ABSTRACT:

Background

Breast cancer (BC) is the most common cancer in women, with triple negative BC (TNBC) accounting for 20% of cases. While early detection and targeted therapies have improved overall life expectancy, TNBC remains resistant to current treatments. Although parity reduces the lifetime risk of developing BC, pregnancy increases the risk of developing TNBC for years after childbirth. Although numerous gene mutations have been associated with BC, no single gene alteration has been identified as a universal driver. RRAS2 is a RAS-related GTPase rarely found mutated in cancer.

Methods

Conditional knock-in mice were generated to overexpress wild type human RRAS2 in mammary epithelial cells. A human sample cohort was analyzed by RT-qPCR to measure RRAS2 transcriptional expre

SUBMITTER: Cifuentes C 

PROVIDER: S-EPMC11234613 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature